Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Galectin Therapeutic (GALT)

Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference GlobeNewswire - Fri Jan 10, 7:00AM CST

GALT : 1.2200 (-0.81%)
Top 5 Biotech Stocks Dominating Retail Investor Conversations In 2024 Stocktwits - Thu Dec 26, 2024

From Tonix Pharmaceuticals’ progress on fibromyalgia treatments to Nvidia-backed Recursion Pharmaceuticals, these stocks sparked significant message volume growth on Stocktwits.

GALT : 1.2200 (-0.81%)
TNXP : 0.3831 (+16.98%)
CDIO : 0.4594 (-8.12%)
CADL : 6.89 (-2.41%)
RXRX : 7.33 (-2.66%)
Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH GlobeNewswire - Fri Dec 20, 2024

GALT : 1.2200 (-0.81%)
Galectin Therapeutics Presents Clinical Data on NAVIGATE Trial for Esophageal Varices in MASH Cirrhosis at AASLD 2024 Quiver Quantitative, Inc. - Mon Nov 18, 2024

Galectin Therapeutics presents NAVIGATE trial findings on portal hypertension in MASH cirrhosis at AASLD 2024. Results expected December 2024.Quiver AI SummaryGalectin Therapeutics, Inc. has announced...

GALT : 1.2200 (-0.81%)
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting GlobeNewswire - Mon Nov 18, 2024

GALT : 1.2200 (-0.81%)
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update GlobeNewswire - Thu Nov 14, 2024

GALT : 1.2200 (-0.81%)
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting GlobeNewswire - Tue Oct 15, 2024

GALT : 1.2200 (-0.81%)
Options - shutterstock_170780711
Rating the Top 4 Unusually Active Call Options From Thursday’s Trading Barchart - Fri Apr 12, 2024

The top four unusually active call options in Thursday trading had an average Vol/OI ratio of 52.25. While that’s not very high, each has compelling reasons to buy. Here's why.

JPM : 264.84 (-0.42%)
FTDR : 58.45 (+0.85%)
GALT : 1.2200 (-0.81%)
KKR : 165.53 (+0.11%)
CPRI : 24.93 (+0.28%)
TPR : 74.65 (+1.40%)
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? Motley Fool - Sun Mar 17, 2024

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

GALT : 1.2200 (-0.81%)
GLMD : 2.93 (-0.32%)
VKTX : 34.50 (-1.26%)
ETNB : 7.13 (+3.03%)
IVA : 2.33 (-7.54%)
SGMT : 4.20 (+1.20%)
TERN : 4.50 (-3.02%)
NVO : 87.97 (+8.47%)
IQV : 204.33 (-0.81%)
MDGL : 328.14 (-3.53%)
Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 Globe Newswire - Tue Jul 26, 2022

NORCROSS, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin...

GALT : 1.2200 (-0.81%)

Barchart Exclusives

3 Dividend Powerhouses To Buy and Hold Amid Market Uncertainty Barchart - Fri Jan 24, 6:00PM CST
Dividend stocks provide steady income, balancing market uncertainty. These three companies are a great place to start. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot